Eli Lilly and Company announced an additional $4.5 billion investment across two manufacturing sites in Lebanon, Indiana, bringing the company’s total Indiana manufacturing commitments since 2020 to more than $21 billion.
The company also officially opened Lilly Lebanon Advanced Therapies, Lilly’s first dedicated genetic medicine manufacturing facility designed to support both clinical and commercial production of advanced genetic therapies.
Lilly said the expanded investment will support additional process technologies and manufacturing capabilities at the Lilly Lebanon API site and the new advanced therapies facility. The Lebanon campus will ultimately include three major facilities: Lilly Lebanon API, Lilly Lebanon Advanced Therapies, and the Lilly Medicine Foundry.
The company noted that the Lebanon API site is expected to become the largest active pharmaceutical ingredient production site in U.S. history when it opens in 2027.
Lilly plans to manufacture several key medicines at the site, including Zepbound (tirzepatide), Mounjaro (tirzepatide), Foundayo (orforglipron), and the investigational obesity and cardiometabolic treatment retatrutide.
The new genetic medicine facility is designed to support a broad range of genetic medicine modalities, from research-stage development through large-scale commercial production. Lilly said the facility required the development of new manufacturing processes due to the lack of established commercial precedent in several advanced therapy categories.
According to Lilly, its total U.S. capital expansion commitments since 2020 now exceed $50 billion.
The company also highlighted the broader economic impact of its Indiana operations. A forthcoming report from Indiana University’s Kelley School of Business found that Lilly accounts for 70% of Indiana’s pharmaceutical GDP and that every Lilly job supports more than two additional jobs across the state.
KEY QUOTES:
“Lilly’s legacy of firsts in Indiana continues today—and the best measure of that legacy is what we do next.”
“From genetic medicines that could one day prevent disease at its source, to Foundayo, a pill making weight loss treatment accessible to millions, we are not just discovering the medicines of the future—we are building the world’s most advanced plants to make them.”
“When our Lebanon API site opens in 2027, it will be the largest API production site in U.S. history, a commitment we chose to build here, at home.”
David A. Ricks, Chair And CEO, Eli Lilly And Company
“This expansion reflects the strength of a long-standing partnership between Lilly and the state of Indiana – one that continues to deliver real results for Hoosiers.”
“With this investment in Lebanon and across the state, Indiana is reinforcing its position as a prime destination for life sciences and advanced manufacturing, spanning innovation, production and global distribution.”
“Together, we are helping lead the future of medicine while creating high-quality jobs and new opportunities for our communities.”
Mike Braun, Governor Of Indiana
“Findings from the Kelley School’s Indiana Business Research Center report demonstrate Lilly’s investments in Indiana are transforming communities across the state in meaningful and far-reaching ways.”
“Lilly’s sustained investments since 2020 underscore the growing strength of Indiana’s life sciences sector.”
“Progress at this scale is possible only through robust partnerships, and Indiana University is moving with purpose alongside Lilly to advance innovation that improves health, prepares a world-class workforce and drives economic vitality.”
Pamela Whitten, President, Indiana University
“Today’s announcement is a milestone for the City of Lebanon, a testament to the strength of our local workforce, and the vitality of our city.”
“Lilly has been an incredible partner, and their decision to further invest in our community ensures that Lebanon will remain at the forefront of the pharmaceutical industry for decades to come.”
Matt Gentry, Mayor Of Lebanon, Indiana
